Drugs / AB-2100
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06245915 | Feb 2024 → Mar 2026 overdue | clear cell renal carcinoma | Arsenal Biosciences, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AB-2100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06245915 ↗ |
| Modality | Cell therapy | “autologous T cell therapy” NCT06245915 ↗ |
| Route | Intravenous | “The AB-2100 cells are given as a single intravenous infusion” NCT06245915 ↗ |